In this project, the candidate proposes to elucidate the genetic basis of important antidepressant response phenotypes in a pre-clinical system, recombinant-inbred intercrosses (RIX) from the Collaborative Cross (CC) mouse lines. Experiments will be performed using fluoxetine (Prozac), a highly prescribed antidepressant. While fluoxetine does not have major side effects, only about 50% of patients experience a therapeutic response. First, we will expose adult male RIX to human-like steady state concentrations of fluoxetine (250 exposed, 250 control cage mates) and assess changes in two phenotypes relevant to antidepressant response in rodents: behavioral despair in the tail suspension test and quantitative measures of hippocampal neurogenesis. For each of these traits, we will use existing genomic data to conduct genome-wide association mapping and pathway analysis. Second, we refine these associations using new and powerful ways to assess the hippocampal dentate gyrus transcriptome and methylome (next generation sequencing technologies). Third, we test the predictive validity of these genetic and molecular biomarkers by generating novel animals expected to show high or low fluoxetine sensitivity (N=10 RIX each). This pre-clinical systems pharmacogenomics project is powered to identify key genes regulating response to fluoxetine in mice. Follow- up work will then examine these candidate genes in human clinical trial samples.
The goal of this study is to understand how fluoxetine (Prozac) works. While it is among the most highly prescribed psychiatric drugs, unfortunately fluoxetine works in only half of all patients. If it were possible to know ahead of time that a patient would not respond to fluoxetine, say by a genetic test, the physician could prescribe a different drug. Since in humans it is very difficult to identify the key genes responsible for inter- individual differences in drug response, this project aims to use mice where conditions can be more tightly regulated. We also propose to use a modern set of technologies to get an in-depth understanding.
|Teng, Brian L; Nikolova, Viktoriya D; Riddick, Natallia V et al. (2016) Reversal of social deficits by subchronic oxytocin in two autism mouse models. Neuropharmacology 105:61-71|
|Didion, John P; Morgan, Andrew P; Yadgary, Liran et al. (2016) R2d2 Drives Selfish Sweeps in the House Mouse. Mol Biol Evol 33:1381-95|
|Crowley, James J; Zhabotynsky, Vasyl; Sun, Wei et al. (2015) Analyses of allele-specific gene expression in highly divergent mouse crosses identifies pervasive allelic imbalance. Nat Genet 47:353-60|
|Wang, WeiBo; Wang, Wei; Sun, Wei et al. (2015) Allele-specific copy-number discovery from whole-genome and whole-exome sequencing. Nucleic Acids Res 43:e90|
|Crowley, James J; Collins, Ann L; Lee, Rebecca J et al. (2015) Disruption of the microRNA 137 primary transcript results in early embryonic lethality in mice. Biol Psychiatry 77:e5-7|
|Sun, Wei; Liu, Yufeng; Crowley, James J et al. (2015) IsoDOT Detects Differential RNA-isoform Expression/Usage with respect to a Categorical or Continuous Covariate with High Sensitivity and Specificity. J Am Stat Assoc 110:975-986|
|Didion, John P; Morgan, Andrew P; Clayshulte, Amelia M-F et al. (2015) A multi-megabase copy number gain causes maternal transmission ratio distortion on mouse chromosome 2. PLoS Genet 11:e1004850|
|Crowley, James J; Kim, Yunjung; Lenarcic, Alan B et al. (2014) Genetics of adverse reactions to haloperidol in a mouse diallel: a drug-placebo experiment and Bayesian causal analysis. Genetics 196:321-47|
|Zou, Fei; Sun, Wei; Crowley, James J et al. (2014) A novel statistical approach for jointly analyzing RNA-Seq data from F1 reciprocal crosses and inbred lines. Genetics 197:389-99|
|Morgan, Andrew P; Crowley, James J; Nonneman, Randal J et al. (2014) The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. PLoS One 9:e115225|
Showing the most recent 10 out of 16 publications